These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32577668)

  • 1. Improving Precision and Power in Randomized Trials for COVID-19 Treatments Using Covariate Adjustment, for Binary, Ordinal, and Time-to-Event Outcomes.
    Benkeser D; Díaz I; Luedtke A; Segal J; Scharfstein D; Rosenblum M
    medRxiv; 2020 Jun; ():. PubMed ID: 32577668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving precision and power in randomized trials for COVID-19 treatments using covariate adjustment, for binary, ordinal, and time-to-event outcomes.
    Benkeser D; Díaz I; Luedtke A; Segal J; Scharfstein D; Rosenblum M
    Biometrics; 2021 Dec; 77(4):1467-1481. PubMed ID: 32978962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimising precision and power by machine learning in randomised trials with ordinal and time-to-event outcomes with an application to COVID-19.
    Williams N; Rosenblum M; Díaz I
    J R Stat Soc Ser A Stat Soc; 2022 Sep; ():. PubMed ID: 36246572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discussion on "Improving precision and power in randomized trials for COVID-19 treatments using covariate adjustment for binary, ordinal, and time-to-event outcomes".
    Proschan MA
    Biometrics; 2021 Dec; 77(4):1482-1484. PubMed ID: 34105763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discussion of "Improving precision and power in randomized trials for COVID-19 treatments using covariate adjustment, for binary, ordinal, and time-to-event outcomes".
    Zhang M; Zhang B
    Biometrics; 2021 Dec; 77(4):1485-1488. PubMed ID: 34105765
    [No Abstract]   [Full Text] [Related]  

  • 8. Rejoinder: Improving precision and power in randomized trials for COVID-19 treatments using covariate adjustment, for binary, ordinal, and time-to-event outcomes.
    Benkeser D; Díaz I; Luedtke A; Segal J; Scharfstein D; Rosenblum M
    Biometrics; 2021 Dec; 77(4):1492-1494. PubMed ID: 34050931
    [No Abstract]   [Full Text] [Related]  

  • 9. Discussion on "Improving precision and power in randomized trials for COVID-19 treatments using covariate adjustment, for binary, ordinal, and time-to-event outcomes" by David Benkeser, Ivan Diaz, Alex Luedtke, Jodi Segal, Daniel Scharfstein, and Michael Rosenblum.
    LaVange LM
    Biometrics; 2021 Dec; 77(4):1489-1491. PubMed ID: 34105762
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19).
    Urwyler P; Charitos P; Moser S; Heijnen IAFM; Trendelenburg M; Thoma R; Sumer J; Camacho-Ortiz A; Bacci MR; Huber LC; Stüssi-Helbling M; Albrich WC; Sendi P; Osthoff M
    Trials; 2021 Jan; 22(1):1. PubMed ID: 33397449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of an ordinal endpoint to time-to-event, longitudinal, and binary endpoints for use in evaluating treatments for severe influenza requiring hospitalization.
    Peterson RL; Vock DM; Babiker A; Powers JH; Hunsberger S; Angus B; Paez A; Neaton JD;
    Contemp Clin Trials Commun; 2019 Sep; 15():100401. PubMed ID: 31312748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Covariate adjustment in randomized controlled trials: General concepts and practical considerations.
    Van Lancker K; Bretz F; Dukes O
    Clin Trials; 2024 Jun; ():17407745241251568. PubMed ID: 38825841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of covariate adjustment approaches under model misspecification in individually randomized trials.
    Tackney MS; Morris T; White I; Leyrat C; Diaz-Ordaz K; Williamson E
    Trials; 2023 Jan; 24(1):14. PubMed ID: 36609282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol.
    Marietta M; Vandelli P; Mighali P; Vicini R; Coluccio V; D'Amico R;
    Trials; 2020 Jun; 21(1):574. PubMed ID: 32586394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive selection of the optimal strategy to improve precision and power in randomized trials.
    Balzer LB; Cai E; Godoy Garraza L; Amaranath P
    Biometrics; 2024 Jan; 80(1):. PubMed ID: 38446441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Covariate adjustment and estimation of difference in proportions in randomized clinical trials.
    Liu J; Xi D
    Pharm Stat; 2024 May; ():. PubMed ID: 38763917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced precision in the analysis of randomized trials with ordinal outcomes.
    Díaz I; Colantuoni E; Rosenblum M
    Biometrics; 2016 Jun; 72(2):422-31. PubMed ID: 26576013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.
    Nanni O; Viale P; Vertogen B; Lilli C; Zingaretti C; Donati C; Masini C; Monti M; Serra P; Vespignani R; Grossi V; Biggeri A; Scarpi E; Galardi F; Bertoni L; Colamartini A; Falcini F; Altini M; Massa I; Gaggeri R; Martinelli G
    Trials; 2020 Jul; 21(1):689. PubMed ID: 32736597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.